PWPS
IKT icon

Pinnacle Wealth Planning Services’s Inhibikase Therapeutics IKT Stock Holding History

Pinnacle Wealth Planning Services’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.07K Hold
5,400
– – ﹤0.01% 2041
2025
Q4 		$11.1K Buy
+5,400
New +$8.59K ﹤0.01% 1970

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Pinnacle Wealth Planning Services's IKT Position: Q1 2026 in Review

Pinnacle Wealth Planning Services held its Inhibikase Therapeutics (IKT) position steady in Q1 2026 at 5,400 shares worth $9.07K. The position accounts for ﹤0.01% of the portfolio, ranked #2041.

Pinnacle Wealth Planning Services first reported a position in IKT in Q4 2025 and has held it in 2 quarters since. The position peaked at $11.1K in Q4 2025. 104 funds tracked by Wall St. Rank hold IKT as of Q1 2026.

  • Pinnacle Wealth Planning Services held 5,400 shares of Inhibikase Therapeutics worth $9.07K as of Q1 2026.
  • Pinnacle Wealth Planning Services left its Inhibikase Therapeutics share count unchanged in Q1 2026.
  • Inhibikase Therapeutics made up ﹤0.01% of Pinnacle Wealth Planning Services's portfolio in Q1 2026, its #2041 holding.
  • Pinnacle Wealth Planning Services first reported a position in Inhibikase Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Pinnacle Wealth Planning Services's Inhibikase Therapeutics position peaked at $11.1K in Q4 2025.
  • 104 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q1 2026.

Based on Pinnacle Wealth Planning Services's 13F filing for Q1 2026, filed 11 May 2026.